成為科學、商業、經營管理交叉點的兩個會議
針對生物醫藥企業的研究開發 (R&D)、業務分析和決策
在不斷變化的當前製藥行業的研究開發 (R&D) 形勢下，藥物開發項目組合管理、組合優先順序、容量管理、資源預測、風險緩解、戰略決策已成為最重要的課題。劍橋健康技術研究所的生物製藥策略系列不僅解釋了製藥和生物技術企業中高層管理人員的決策過程，還提供高層次的討論、互動式分組會議、人脈建立機會、小規模對話、以及一對一的個別會議。與會者可以獲得新工具和組織戰略，並將其用於項目規劃、項目組合分析和決策優化。同時，能夠根據項目組合的優先級進行資源的規劃、配置和容量管理。
相關組織
2024年主題演講嘉賓
Michelle Shogren
CEO & Owner, Innovate in What You Do!
Senior Director of Innovation, Pharma R&D Clinical Operations, Bayer
Mary Lou Panzano
Founder and CEO, Panzano Enterprises LLC
Former Vice President, Internal Communications, Bayer
Helen J. Merianos, PhD
Head, R&D Portfolio Strategy, Sanofi
Michael Myers, PhD
Associate Vice President, LRL, Project Management-Due Diligence, Eli Lilly and Company
Peter Ray
Vice President, Head of, Portfolio Analytics, Novartis
Leslie Lippard
Senior Director, Portfolio, Analytics, Alnylam
2024年Advisory Board
Michael Ferrante
Executive Director, Portfolio Prioritization, Global Regulatory Affairs & Clinical Safety, Merck
Sean Gallagher
Director, Capacity Management and Business Analytics, Janssen
Leslie Lippard
Senior Director, Portfolio Analytics, Alnylam Pharmaceuticals
Michael Myers
Associate Vice President, LRL Project Management - Due Diligence, Eli Lilly & Co.
Joe Stalder
Vice President, Program Management, Zentalis Pharmaceuticals
